tirzepatide vs dulaglutide Frontiers Tirzepatide Offers Superior Kidney Protection

In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)

95% CI 0.600.88), DPP-4i (aHR, 0.72

USAGE [email protected]

Learn what color semaglutide should be, why discoloration matters for safety, and what to do if your Ozempic or Wegovy appears abnormal

This guide reviews clinical evidence, provider consultation frameworks, and personalized approaches to GLP-1 therapy in post-cholecystectomy patients

Uterine fibroids are benign neoplasms of the uterus and are a major source of morbidity in women of reproductive age